Regression of human colon cancer xenografts in SCID mice following oral administration of water-insoluble camptothecins

International Journal of Oncology

Volumn 10, Issue 5, 1997, Pages 953-960

  Cai, Qiuyin ^a,c   Russell Lindsey, J ^b,c   Zhang, Ruiwen ^a,c  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

10 hydroxycamptothecin; camptothecin; chemotherapy; colon cancer; human cancer xenografts

Indexed keywords

10 HYDROXYCAMPTOTHECIN; CAMPTOTHECIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COLON CANCER; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SCID MOUSE; TUMOR REGRESSION; TUMOR XENOGRAFT;

EID: 12644284501     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.10.5.953     Document Type: Article

References (25)

1. Mandel JS: Screening for colon and rectal cancer. Cancer Cont 3: 170-177, 1996.
2. Wall ME, Wani MC, Cook CE, Palmer KH, Mcphail AT and Sim GA: Plant antitumor agents: I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc 88: 3888-3890, 1966.
3. Horwitz SB and Honvotz MS: Effects of camptothecin on the breakage and repair of DNA during the cell cycle. Cancer Res 33: 2834-2836, 1973.
4. Kessel D: Effects of camptothecin on RNA synthesis in leukemia L1210 cells. Biochem Biophys Acta 246: 225, 1971.
5. Gallo RC, Whang-Peng J and Adamson RH: Studies on the antitumor activity, mechanism of action, and cell cycle effects of camptothecin. J Natl Cancer Inst 46: 789-795, 1971.
6. Gottlich JA, Guarino AM, Call JB and Block JB: Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880). Cancer Chemother Rep 54: 461-470, 1970.
7. Creven PR, Allen LM and Muggia FM: Plasma camptothecin (NSC-100880) levels during a 5-day course of treatment: relation to dose and toxicity. Cancer Chemother Rep 56: 573-578, 1972.
8. Creaven PR and Allen LM: Renal clearance of camptothecin (NSC-100880): effect of urine volume. Cancer Chemother Rep 57: 175-184, 1973.
9. Muggia FM, Creaven PJ, Hansen HH, Cohen MH and Selawry OS: Phase I clinical trial weekly and daily treatment of camptothecin (NSC-100880): correlation with preclinical studies. Cancer Chemother Rep 56: 515-521, 1972.
10. Moertel CG, Schutt AJ, Reitemeier RJ and Hahn RG: Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother Rep 6: 95-101, 1972.
11. Gottlieb JA and Luce JK: Treatment of malignant of melanoma with camptothecin (NSC-100880). Cancer Chemother Rep 56: 103-105, 1972.
12. Hsiang Y-H, Hertzberg R, Hecht S and Liu LF: Camptothecin induced protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260: 14873-14878, 1985.
13. Chabner BA: Camptothecin. J Clin Oncol 10: 3-4, 1992.
14. Slichnmycr WR, Rowinsky EK, Donchower RC and Kaufmann SH: The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst 85: 271-291, 1993.
15. Creemers GJ, Lund B and Verweij J: Topoisomerase I inhibitors: topotecan and irinotecan. Cancer Treatment Rev 20: 73-96, 1994.
16. Potmesil M: Camptothecin from bench research to hospital wards. Cancer Res 54: 1431-1439, 1994.
17. Wani MC, Nicholas AW, Manikumar G and Wall ME: Plant antitumor agents: 25. Total synthesis and antileukemic activity of ring A substituted camptothecin analogues. Structure-activity correlations. J Med Chem 30: 1774-1779, 1987.
18. Jaxel C, Kuhn KW, Wani MC, Wall ME and Pommier Y: Structure-activity study of the actions of camptothecin derivatives of mammalian topoisomerase I: evidence for specific receptor site and a relation to antitumor activity. Cancer Res 49: 1465-1469, 1989.
19. Hertzberg RP, Caranfa MJ, Holden KG, Jakas DR, Gallagher G, Mattern MR, Mong S-M, Bartus JO, Johnson RK and Kingsbury WD: Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. J Med Chem 32: 715-720, 1989.
20. Hertzberg RP, Caranfa MJ and Hecht SM: On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex. Biochemistry 28: 4629-4638, 1989.
21. Tanizawa A, Fujimori A, Fujimori Y and Pommier Y: Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J Natl Cancer Inst 86: 836-842, 1994.
22. Kawato Y, Aonuma M, Hirota Y, Kuga H and Sato K: Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 51: 4187-4191, 1991.
23. Rothenberg ML, Kuhn JG, Butrris HA, Nelson J, Eckardt JR, Tristan-Morales M, Hilsenbeck SG, Weiss GR, Smith LS, Rodriguez GI, Rock MK and von Hoff DD: Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol 11: 2194-2204, 1993.
24. De Forni M, Bugat R, Chabot GG, Culine S, Extra J-M, Gouyette A, Madelaine I, Marty ME and Mathieu-Boué A: Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients. Cancer Res 54: 4347-4354, 1994.
25. Negoro S, Fukuoka M, Masuda N, Takada M, Kusunoki Y, Matsui K, Takiuji N, Kudoh S, Niita H and Taguchi T: Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. J Natl Cancer Inst 83: 1164-1168, 1991.